Analyst Price Targets — DBVT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 18, 2025 11:46 am | Andrew Fein | H.C. Wainwright | $40.00 | $22.55 | StreetInsider | DBV Technologies S.A (DBVT) PT Raised to $40 at H.C. Wainwright |
| December 17, 2025 1:10 pm | Kristen Kluska | Cantor Fitzgerald | $48.00 | $22.92 | TheFly | DBV Technologies price target raised to $48 from $42 at Cantor Fitzgerald |
| December 17, 2025 9:32 am | Yatin Suneja | Guggenheim | $51.00 | $17.98 | StreetInsider | DBV Technologies S.A (DBVT) PT Raised to $51 at Guggenheim |
| December 15, 2025 11:39 am | Andrew Fein | H.C. Wainwright | $35.00 | $19.11 | StreetInsider | DBV Technologies S.A (DBVT) PT Raised to $35 at H.C. Wainwright |
| December 14, 2025 11:55 pm | Kristen Kluska | Cantor Fitzgerald | $42.00 | $18.38 | TheFly | DBV Technologies initiated with an Overweight at Cantor Fitzgerald |
| December 3, 2025 11:12 am | — | Guggenheim | $35.00 | $12.90 | TheFly | DBV Technologies initiated with a Buy at Guggenheim |
| May 5, 2025 10:08 am | Andrew Fein | H.C. Wainwright | $16.00 | $9.25 | TheFly | DBV Technologies price target raised to $16 from $7 at H.C. Wainwright |
Latest News for DBVT
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group Approximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by…
Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present…
Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DBVT.
U.S. House Trading
No House trades found for DBVT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.